LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/Zimmer Biomet Wins Appeal Over $9 Million Durom Hip Damage Award
Legal & Regulatory and Reimbursement

Zimmer Biomet Wins Appeal Over $9 Million Durom Hip Damage Award

May 4, 2018 2 min read Premium comments

Advertisement

Zimmer Biomet Wins Appeal Over $9 Million Durom Hip Damage Award
Photo creation by RRY Publications LLC
#zimmerbiometSecondary#hippain#lawsuits

A California appellate court has reversed a $9 million damage award against Zimmer Biomet Holdings, Inc. over the Durom Cup hip implant and granted the company a new trial to determine new, if any, damages. The court did not grant the company a new trial over liability, however.

Plaintiff Lawyer’s Loose Lips

The April 27, 2018 appellate decision, reported by Law360, cited comments by the plaintiff’s lawyer “about Zimmer’s value, passing reference to a recall of a different product and an indication that the Durom Cup isn’t sold anymore.” The appellate court also noted statements about the patient’s medical expenses.

According to court documents, after the suit was filed in 2010 against then Zimmer, Inc., a jury found the company negligently designed the Durom Cup, harming Gary Kline, the plaintiff, and failed to warn him about potential risks. The jury awarded Kline $153,317 in past medical expenses, even though the parties had already agreed that Kline’s medical expenses were about $73,000. The jury also awarded Kline $2.4 million for past noneconomic loss and $6.6 million for future noneconomic loss, according to court documents.

The trial court subsequently reduced the award of economic damages to roughly $73,000 but granted Zimmer Biomet a new trial for excessive noneconomic damages as well as the loose statements made by Kline’s attorney.

Kline appealed the ruling for a new trial.

The appeals court upheld the order for a new trial on damages because the trial court adequately considered evidence about Kline’s past and future pain when concluding the $9 million awarded was too high, according to the court filing reported by Law360.

No Redo on Liability

Advertisement

However, the appeals court did not agree to give Zimmer Biomet a new trial on liability, concluding Kline’s lawyer’s comments did not affect the jury’s liability finding.

The appeals court, according to court documents, determined that any prejudice was limited to the damages verdict. The trial court shut down any reference to a recall and struck from the record the statement the product is no longer sold.

“Kline’s counsel’s misconduct was not so pervasive nor so egregious that it prevented the jury from rationally considering the evidence admitted at trial,” the filing said.

“Gary Kline is gratified that the Court of Appeal agreed that Zimmer is responsible for his injuries and looks forward to the opportunity to prove to a jury the substantial damages that Zimmer caused him with its defective Durom Cup hip implant,” his counsel Michael Gurien of Waters Kraus & Paul told Law360 by email.

No date for a new trial was reported.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy